Cargando…

Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors

BACKGROUND/AIM: It is not always easy to diagnose pulmonary neuroendocrine tumors (PNETs). The aim of the present study is to make a differential diagnosis by studying the same markers in patients with non-small-cell lung carcinoma (NSCLC), patients with benign lung disease (chronic obstructive pulm...

Descripción completa

Detalles Bibliográficos
Autores principales:	TUTAR, Nuri, YETKİN, Nur Aleyna, YAZICI, Cevat, ÖNAL, Ömer, KONTAŞ, Olgun, KELEŞTEMUR, Fahrettin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Scientific and Technological Research Council of Turkey 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018342/ https://www.ncbi.nlm.nih.gov/pubmed/31091854 http://dx.doi.org/10.3906/sag-1810-147

Ejemplares similares

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
por: Baudin, E., et al.
Publicado: (1998)

Aptamer based surface plasma resonance assay for direct detection of neuron specific enolase and progastrin-releasing peptide (31-98)
por: Sun, Linlin, et al.
Publicado: (2021)

Instability of Plasma and Serum Progastrin-Releasing Peptide During Repeated Freezing and Thawing
por: Lee, Jae-Eun, et al.
Publicado: (2016)

Increased Progastrin-Releasing Peptide Expression is Associated with Progression in Gastric Cancer Patients
por: Li, Li, et al.
Publicado: (2020)

Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
por: Tomita, Tatsuo
Publicado: (2020)

Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring
por: Barchiesi, Vittoria, et al.
Publicado: (2021)

Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
por: Paik, Woo Hyun, et al.
Publicado: (2013)

Targeting progastrin enhances radiosensitization of colorectal cancer cells
por: Kowalski-Chauvel, Aline, et al.
Publicado: (2017)

hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022)

Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers
por: Gaiser, Maria Rita, et al.
Publicado: (2015)

Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy
por: Li, Ming, et al.
Publicado: (2020)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
por: Di Giacinto, Paola, et al.
Publicado: (2018)

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
por: Baekdal, Jonas, et al.
Publicado: (2020)

Association between Serum Progastrin Biomarker Level and Gastric Cancer
por: Amjadi, Omolbanin, et al.
Publicado: (2022)

A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours
por: Bernini, G P, et al.
Publicado: (2001)

Commentary to “Chromogranin A: Biological Function and Clinical Utility in Neuroendocrine Tumor Disease”
por: Jeske, Wojciech, et al.
Publicado: (2010)

Chromogranin A and Its Fragments as Regulators of Small Intestinal Neuroendocrine Neoplasm Proliferation
por: Giovinazzo, Francesco, et al.
Publicado: (2013)

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
por: Gut, Paweł, et al.
Publicado: (2016)

Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
por: Tseng, Chao-Ming, et al.
Publicado: (2018)

Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations
por: Dong, Juanjuan, et al.
Publicado: (2021)

Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China
por: Wu, Xiao‐Yuan, et al.
Publicado: (2018)

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas
por: Qiao, Xin-Wei, et al.
Publicado: (2014)

Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors
por: van Adrichem, R C S, et al.
Publicado: (2013)

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors
por: Hijioka, Masayuki, et al.
Publicado: (2014)

Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
por: Wang, Yu-hong, et al.
Publicado: (2014)

Acute effects of N‐terminal progastrin fragments on gastric acid secretion in man
por: Goetze, Jens P., et al.
Publicado: (2017)

Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours
por: Korse, C M, et al.
Publicado: (2011)

Diagnostic Value of Circulating Chromogranin A for Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
por: Yang, Xin, et al.
Publicado: (2015)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Tian, Tiantian, et al.
Publicado: (2016)

Chromogranin A Tubulopathy: Differing Histopathologic Patterns of Acute Tubular Injury in the Setting of Neuroendocrine Neoplasms
por: Sekulic, Miroslav, et al.
Publicado: (2019)

Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors
por: Kövesdi, Annamária, et al.
Publicado: (2020)

NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis
por: Malczewska, Anna, et al.
Publicado: (2020)

The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors – A Single-Center Experience
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Differences in skin lesions of endogenous and exogenous Cushing’s patients
por: Erden, Fatma, et al.
Publicado: (2018)

Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
por: Nölting, Svenja, et al.
Publicado: (2012)

Low Efficacy of Chromogranin A Elimination by Therapeutic Plasma Exchange for Treatment of Chromogranin A Tubulopathy
por: Hakroush, Samy, et al.
Publicado: (2021)

Progastrin Represses the Alternative Activation of Human Macrophages and Modulates Their Influence on Colon Cancer Epithelial Cells
por: Hernández, Carlos, et al.
Publicado: (2014)

The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
por: You, Benoit, et al.
Publicado: (2019)

Prognostic Value of Plasma hPG(80) (Circulating Progastrin) in Metastatic Renal Cell Carcinoma
por: Kohli, Manish, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8s7a6a5e8j59k57g9uc7mjd72g